Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | D820E |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | KIT D820E lies within the protein kinase domain of the Kit protein (UniProt.org). D820E has been associated with secondary drug resistance (PMID: 19861442), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, Nov 2024). |
Associated Drug Resistance | Y |
Category Variants Paths |
KIT mutant KIT exon17 KIT D820E |
Transcript | NM_000222.3 |
gDNA | chr4:g.54733168T>G |
cDNA | c.2460T>G |
Protein | p.D820E |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_005265741 | chr4:g.54733168T>G | c.2460T>G | p.D820E | RefSeq | GRCh38/hg38 |
XM_005265741.1 | chr4:g.54733168T>G | c.2460T>G | p.D820E | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54733168T>G | c.2460T>G | p.D820E | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54733168T>G | c.2460T>G | p.D820E | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54733168T>G | c.2460T>G | p.D820E | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54733168T>G | c.2460T>G | p.D820E | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT D820E | Advanced Solid Tumor | sensitive | Nintedanib | Preclinical - Cell culture | Actionable | In a preclinical study, Ofev (nintedanib) inhibited Kit autophosphorylation and proliferation of transformed cells expressing KIT D820E in culture (PMID: 35194937). | 35194937 |
KIT D820E | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical | Actionable | In a preclinical study, cells expressing KIT D820E demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608). | 25239608 |
KIT D820E | thymic carcinoma | predicted - sensitive | Sorafenib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with metastatic thymic carcinoma harboring KIT D820E demonstrated a partial response to treatment with Nexavar (sorafenib) (PMID: 19461405). | 19461405 |